181 related articles for article (PubMed ID: 25134067)
1. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants.
Araki S; Suga S; Miyake F; Ichikawa S; Kinjo T; Yamamoto Y; Kusuhara K
Early Hum Dev; 2014 Oct; 90(10):607-11. PubMed ID: 25134067
[TBL] [Abstract][Full Text] [Related]
2. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
3. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
4. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
Jin K; Park BS; Kim YW; Vaziri ND
Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
[TBL] [Abstract][Full Text] [Related]
5. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
[TBL] [Abstract][Full Text] [Related]
6. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
7. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
[TBL] [Abstract][Full Text] [Related]
8. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration.
Miyazawa H; Honda T; Miyauchi S; Domon H; Okui T; Nakajima T; Tabeta K; Yamazaki K
Clin Chim Acta; 2012 Jan; 413(1-2):154-9. PubMed ID: 22001517
[TBL] [Abstract][Full Text] [Related]
9. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
[TBL] [Abstract][Full Text] [Related]
10. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
Gauthier MS; Pérusse JR; Awan Z; Bouchard A; Tessier S; Champagne J; Krastins B; Byram G; Chabot K; Garneau P; Rabasa-Lhoret R; Faubert D; Lopez MF; Seidah NG; Coulombe B
Methods; 2015 Jun; 81():66-73. PubMed ID: 25770357
[TBL] [Abstract][Full Text] [Related]
11. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
12. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
13. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
Abujrad H; Mayne J; Ruzicka M; Cousins M; Raymond A; Cheesman J; Taljaard M; Sorisky A; Burns K; Ooi TC
Atherosclerosis; 2014 Mar; 233(1):123-9. PubMed ID: 24529132
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
15. Serum PCSK9 levels in infants with deviant birth weight: a biomarker of the lipoprotein metabolism.
Vlahos A; Rallis D; Lianou A; Baltogianni M; Dermitzaki N; Maragoudaki E; Papastergiou E; Tzallas C; Tsabouri S; Makis A; Siomou E; Milionis H; Giapros V
J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2188108. PubMed ID: 36906794
[TBL] [Abstract][Full Text] [Related]
16. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
17. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.
Ghosh M; Gälman C; Rudling M; Angelin B
J Lipid Res; 2015 Feb; 56(2):463-9. PubMed ID: 25535288
[TBL] [Abstract][Full Text] [Related]
18. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.
Xu RX; Li S; Zhang Y; Li XL; Guo YL; Zhu CG; Li JJ
Lipids Health Dis; 2014 Dec; 13():188. PubMed ID: 25496400
[TBL] [Abstract][Full Text] [Related]
19. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.
Persson L; Cao G; Ståhle L; Sjöberg BG; Troutt JS; Konrad RJ; Gälman C; Wallén H; Eriksson M; Hafström I; Lind S; Dahlin M; Amark P; Angelin B; Rudling M
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2666-72. PubMed ID: 20884874
[TBL] [Abstract][Full Text] [Related]
20. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
